XERS - Xeris: Recent Success Warrants A Closer Look

• Xeris Pharmaceuticals continues to pop up on my newsfeed and momentum scanners. Unfortunately, I threw XERS in my speculative portfolio's closet and haven't paid attention despite it hitting new 52-week highs.
• The company recently received European approval for their premixed RTU liquid glucagon auto-injector for very low blood sugar.
• Xeris has an impressive platform technology that can generate premixed RTU formulations that could change the healthcare system.
• Despite a long hiatus, my investment thesis is still intact and appears to be strengthening. I reveal my plans to add to my XERS position in the coming weeks.

For further details see: